S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

TelyRx Partners with SISTERLY to Expand Menopause Care

Navigating the complexities of perimenopause and menopause now comes with a new option in the digital pharmacy space. TelyRx is integrating SISTERLY’s science-backed nutritional supplements into its platform, marking the first time the Irish wellness brand’s flagship multivitamin will be available to consumers through a U.S. pharmacy partner.

TelyRx Partners with SISTERLY to Expand Menopause Care
Photo: Bio & News

The collaboration introduces The Elevator, a daily powder sachet containing 23 nutrients, to TelyRx’s existing prescription-based menopause offerings. By combining clinical medication access with targeted nutritional support, the company aims to move toward a more holistic model of care for women in midlife. The supplement, developed by a team of doctors and scientists, focuses on energy, immune function, and hormonal regulation.

Vanessa Slowey, CEO of TelyRx, emphasized that the expansion reflects the reality that menopause symptoms vary widely between individuals. The addition of SISTERLY’s product allows the platform to offer a spectrum of choices rather than a one-size-fits-all approach. For SISTERLY co-founder Jennifer O'Connell, the partnership serves as a strategic move to scale the reach of their science-led formulations within the U.S. market. The rollout coincides with World Menopause Month, reinforcing the platform's focus on broadening its women's health portfolio.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!